Kite Pharma’s Post

#LandmarkPaper in Hematology: the International Prognostic Index (IPI) published in 1993 is a simple 5-variable prognostic model built for patients with aggressive B-cell lymphoma; today, 30 years later, it remains the standard for patient prognostication and determination of clinical trial eligibility. https://lnkd.in/dzyfMGnJ

News from the Inovia Bio Team! This Saturday we'll be presenting our latest study "Why We Fail: An Analysis of Terminated Interventional Clinical Trials in Lymphoma" at the American Society of Hematology (ASH) in San Diego. We'll be sharing insightful findings on the reasons behind certain lymphoma trial failures and, more importantly, strategies for preventing these setbacks in future research. Come and see us at hall G-H, poster n.1743, from 5:30 PM! #InoviaBio #DrugDevelopment #InovaSight

This study on long-term follow-up in relapsed mantle cell lymphoma involved a combination of lenalidomide, rituximab, and ibrutinib. Conducted in the Nordic countries, it showed a median progression-free survival of 70.4 months, even in TP53 mutated cases. Elin Forsgren, Uppsala University, presents the study in this MEDtalk at the European Hematology Association (EHA) 2024. 🔗See more from the EHA congress; https://lnkd.in/dPW-ansy  #EHA24 #Hematology

This study on long-term follow-up in relapsed mantle cell lymphoma involved a combination of lenalidomide, rituximab, and ibrutinib. Conducted in the Nordic countries, it showed a median progression-free survival of 70.4 months, even in TP53 mutated cases. Elin Forsgren, Uppsala University, presents the study in this MEDtalk at the European Hematology Association (EHA) 2024. 🔗See more from the EHA congress;  https://lnkd.in/d8jmcNPw #EHA24 #Hematology

ALLG is advancing AML research through a new trial #AMLM22 CADENCE, a new collaboration with Mendus AB!

JUST IN: FDA investigates potential link between CAR T-cell therapy and T-cell lymphoma cases. Experts emphasize the need for more data. #CARtherapy #TcellLymphoma #MedicalResearch #TheReportify. Share your thoughts in the comments. To learn more and read the complete story, click on this link. https://lnkd.in/gswxHfFc

Global CD3 Antibodies Market Research Report 2023-2028: Steady Growth with Multiple Myeloma, Lymphoma, and Leukemia Indications, Clinical Development Focuses on Cancer Indications: DUBLIN, Dec. 14, 2023 /PRNewswire/ -- The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. CD3 protein has emerged as a promising target that has significant therapeutic potential in various...

CNS lymphoma market Report 2023-2033 | Trends and Future Growth https://lnkd.in/e5ifw42H #marketanalysis #marketresearch #marketresearchreports #businessintelligence

Join us on March 7th for a webinar and panel discussing the role of ultra-sensitive ctDNA in clinical trials in B-cell lymphomas. Our presenters will share recent data utilizing our PhasED-Seq assay and answer audience Q&A live. Register today! https://t.ly/Zbejt Learn more about PhasED-Seq and our recent data: https://t.ly/M-kXY #mrd #ctdna #lymphoma #clinicaltrials #precisionmedicine

Kymera Therapeutics presents new clinical data from the ongoing Phase 1 trial of potent, highly selective STAT3 Degrader KT-333, a historically undrugged transcription factor at EHA Annual Meeting KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor Well-tolerated with Phase 1 dose escalation ongoing and additional data expected in the second half of 2024 https://lnkd.in/gxFube6Z